Your session is about to expire
← Back to Search
N/A
Transfusion for Heart Attack (MINT Trial)
N/A
Waitlist Available
Led By Paul Hébert, MD
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time frame: 6 months
Awards & highlights
MINT Trial Summary
This trial will compare two different strategies of blood transfusion for heart attack patients to see which is more effective.
Eligible Conditions
- Heart Attack
MINT Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ time frame: 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time frame: 6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Enrollment rate
Non-adherence
Secondary outcome measures
Recurrent non-fatal myocardial infarction
Side effects data
From 2014 Phase 3 trial • 118 Patients • NCT0000313831%
Fatigue
23%
Pulmonary
15%
Infection
8%
Cardiac adverse event
8%
Diarrhea
8%
Esophagitis
8%
Hot flashes
8%
Other toxicities
8%
Hemorrhage
8%
Skin
8%
Weight loss
8%
Neuropathy-clinical
8%
Edema
8%
Anemia
8%
Neuropathy-psych
8%
Abdominal cramps
100%
80%
60%
40%
20%
0%
Study treatment Arm
Erythropoietin (300 Units/kg) and Filgrastim (Step 4)
Supportive Care (Step 1)
Erythropoietin (Step 1)
Erythropoietin (Cross-over; Step 2)
Erythropoietin (150 Units/kg) and Filgrastim (Step 3)
MINT Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Restrictive Transfusion StrategyExperimental Treatment1 Intervention
We will permit but not require red cell transfusions once a hemoglobin value falls below 80 g/L (required below 70 g/L) during the 30 days following randomization
Group II: Liberal Transfusion StrategyActive Control1 Intervention
We will transfuse at a transfusion threshold of 100 g/L for up to 30 days after randomization.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transfusion
2021
Completed Phase 3
~7150
Find a Location
Who is running the clinical trial?
Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
366 Previous Clinical Trials
126,136 Total Patients Enrolled
Canadian Blood ServicesOTHER
20 Previous Clinical Trials
17,138 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,341 Previous Clinical Trials
26,449,212 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have already been part of the MINT Trial before.If you are in the hospital and have a low hemoglobin level and are diagnosed with a specific type of heart attack.Your heart test shows high levels of a specific marker, called cardiac troponin.You have symptoms or signs of a heart problem, such as changes in your heart's electrical signals or evidence of reduced blood flow to the heart.You are currently experiencing severe bleeding that requires immediate blood transfusion.You do not want to receive a blood transfusion.You have a heart surgery scheduled or just had a recent heart surgery.The medical team has decided not to pursue aggressive treatment for the patient.
Research Study Groups:
This trial has the following groups:- Group 1: Restrictive Transfusion Strategy
- Group 2: Liberal Transfusion Strategy
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Does this investigation currently accept enrollees?
"As confirmed on clinicaltrials.gov, this medical trial is not currently looking for enrollees. This particular study was initially announced on June 30th 2016 and its latest update took place in July 24th 2023. Although it has now concluded recruitment, there are 1162 other trials actively seeking participants at the moment."
Answered by AI
Could you provide a detailed account of the number of sites that are presently running this investigation?
"Currently, 4 medical centres are enrolling patients for this clinical trial. These include Victoria Heart Institute in Victoria, Centre Hospitalier de l'Universite de Montreal-Hotel Dieu in Montreal, and Institut Universitaire de Cardiologie et Pneumologie in Quebec City as well as other sites scattered throughout the country."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger